Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised,placebo-controlled,double-blind study

Abstract

Antidiabetic thiazolidinediones (TZDs) improve endothelial function in patients with or without type 2 diabetes. The present randomised, placebo-controlled, double-blind study examined the time course of a single dose of rosiglitazone on flow-mediated endothelium-dependent vasodilation (FMD), metabolic parameters, and its effect on inflammatory markers in non-diabetic men. Forty non-obese, healthy men with normal glucose tolerance were randomised to a single dose of rosiglitazone (8 mg) or placebo, and FMD was assessed at baseline as well as after 6 h and 24 h. Rosiglitazone did not significantly affect blood glucose and insulin levels or lipid parameters after 6 and 24 h compared with placebo. Treatment with rosiglitazone significantly increased FMD after 6 h from 4.3% (3.3; 4.9) to 7.6% (5.6; 9.2) (p<0.0001 vs. baseline) resulting in a highly significant effect compared with placebo (p<0.0001 for difference between groups). After 24 h FMD was still significantly higher in the rosiglitazone group compared with baseline (p=0.001), but the effect was no longer statistically significant versus placebo (p=0.171). Our study shows a very rapid effect of single dose rosiglitazone treatment on endothelial function in non-diabetic healthy men, underscoring the hypothesis that TZDs may exhibit direct effect in the vasculature independent of their metabolic action.

Keywords

endothelial function thiazolidinediones inflammation

References

Behrendt, D. , Ganz, P. (2002) Endothelial function. From vascular biology to clinical applications. Am J Cardiol 90(10C):40L-8L.

De Caterina, R. , Libby P. , Peng H.B. , et al. (1995) Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines . J Clin Invest 96(1):60-8.

Ganz, P. , Vita, J.A. ( 2003) Testing endothelial vasomotor function: nitric oxide, a multipotent molecule. Circulation 108(17):2049-53.

Kinlay, S. , Libby. P. , Ganz, P. ( 2001) Endothelial function and coronary artery disease. Curr Opin Lipidol 12(4):383-9.

Gimbrone, M.A. , Jr. , Cybulsky, M.I. , Kume, N. , Collins, T. , Resnick, N. (1995) Vascular endothelium. An integrator of pathophysiological stimuli in atherogenesis. Ann N Y Acad Sci 748:122-31; discussion 31-2.

Dupuis, J. , Tardif, J.C. , Cernacek, P. , Theroux, P. ( 1999) Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 99(25):3227-33.

Laufs, U. , Wassmann, S. , Hilgers, S. , Ribaudo, N. , Bohm, M. , Nickenig, G. ( 2001) Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 88(11):1306-7.

Murakami, T. , Mizuno, S. , Ohsato, K. , et al. (1999) Effects of troglitazone on frequency of coronary vasospasticinduced angina pectoris in patients with diabetes mellitus. Am J Cardiol 84(1):92-4.

Pistrosch, F. , Passauer, J. , Fischer, S. , Fuecker, K. , Hanefeld, M. , Gross, P. (2004) In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 27:484-90.

10.

Caballero, A.E. , Saouaf, R. , Lim, S.C. , et al. (2003) The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 52(2):173-80.

11.

Wang, T.D. , Chen, W.J. , Lin, J.W. , Chen, M.F. , Lee, Y.T. ( 2004) Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 93(3):362-5.

12.

Hetzel, J. , Balletshofer, B. , Rittig, K. , et al. (2005) Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 25:1804-9.

13.

Calnek, D.S. , Mazzella, L. , Roser, S. , Roman, J. , Hart, C.M. ( 2003) Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 23(1):52-7.

14.

Celermajer, D.S. , Sorensen, K.E. , Gooch, V.M. , et al. (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis . Lancet 340(8828): 1111-5.

15.

Balletshofer, B.M. , Goebbel, S. , Rittig, K. , et al. (2001) Einfluss der Untersuchererfahrung auf intra- und interindividuelle Variabilitat bei der Erfassung der peripheren Endothelfunktion mittels hochauflosendem Ultraschall. Ultraschall Med 22(5):231-5.

16.

Joannides, R. , Haefeli, W.E. , Linder, L. , et al. (1995) Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 91(5):1314-9.

17.

Corretti, M.C. , Anderson, T.J. , Benjamin, E.J. , et al. (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39(2):257-65.

18.

Schwedhelm, E. , Maas, R. , Tan-Andresen, J. , Schulze, F. , Riederer, U. , Boger, R.H. (2007) High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 851(1-2):211-9.

19.

Koenig, W. , Rothenbacher, D. , Hoffmeister, A. , Griesshammer, M. , Brenner, H. ( 2001) Plasma fibrin D-dimer levels and risk of stable coronary artery disease: results of a large case-control study. Arterioscler Thromb Vasc Biol 21(10):1701-5.

20.

Dandona ( 2001) Diabetologia 44(Suppl 1):A36

21.

Kanda, T. , Brown, J.D. , Orasanu, G. , et al. (2009) PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. J Clin Invest 119(1):110-24.

22.

Cominacini, L. , Young, M.M. , Capriati, A. , et al. (1997) Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers . Diabetologia 40(10):1211-8.

23.

Raskin, P. , Rappaport, E.B. , Cole, S.T. , Yan, Y. , Patwardhan, R. , Freed, M.I. ( 2000) Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 43(3):278-84.

24.

Hammarstedt, A. , Andersson, C.X. , Rotter Sopasakis , V. , Smith, U. (2005) The effect of PPARgamma ligands on the adipose tissue in insulin resistance . Prostaglandins Leukot Essent Fatty Acids 73(1):65-75.

25.

Riera-Guardia, N. , Rothenbacher, D. (2008) The effect of thiazolidinediones on adiponectin serum level: a meta-analysis. Diabetes Obes Metab 10(5):367-75.

26.

Balletshofer, B.M. , Rittig, K. , Enderle, M.D. , et al. (2000) Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 101(15):1780-4.

27.

Otto, M.E. , Svatikova, A. , Barretto, R.B. , et al. (2004) Early morning attenuation of endothelial function in healthy humans. Circulation 109(21):2507-10.

28.

Bevilacqua, M.P. , Stengelin, S. , Gimbrone, M.A., Jr. , Seed, B. (1989) Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 243(4895):1160-5.

29.

Boger, R.H. (2006) Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 38(2):126-36.

30.

Stuhlinger, M.C. , Abbasi, F. , Chu, J.W. , et al. (2002) Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor . JAMA 287(11):1420-6.

31.

Wang, T.D. , Chen, W.J. , Cheng, W.C. , Lin, J.W. , Chen, M.F. , Lee, Y.T. ( 2006) Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol 98(8):1057-62.

32.

Chaudhry, J. , Ghosh, N.N. , Roy, K. , Chandra, R. (2007) Antihyperglycemic effect of a new thiazolidinedione analogue and its role in ameliorating oxidative stress in alloxaninduced diabetic rats. Life Sci 80(12):1135-42.

33.

Sidhu, J.S. , Cowan, D. , Kaski, J.C. (2004) Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am J Cardiol 64(2):151-6.

34.

Hanefeld, M. , Marx, N. , Pfutzner, A. , et al. (2007) Antiinflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 49(3):290-7.

35.

Pfutzner, A. , Marx, N. , Lubben, G. , et al. (2005) Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 45(12):1925-31.

36.

Sidhu, J.S. , Kaposzta, Z. , Markus, H.S. , Kaski, J.C. (2004) Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 24(5):930-4.

37.

Sidhu, J.S. , Cowan, D. , Tooze, J.A. , Kaski, J.C. (2004) Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. Am Heart J 147(6):e25.

38.

Nissen, S.E. , Wolski, K. ( 2007) Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med 356(24): 2457-71.

39.

Singh, S. , Loke, Y.K. , Furberg, C.D. ( 2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. Jama 298(10):1189-95.

40.

Home, P.D. , Pocock, S.J. , Beck-Nielsen, H. , et al. (2007) Rosiglitazone Evaluated for Cardiovascular Outcomes - An Interim Analysis. N Engl J Med 357(1): 28-38.